A citation-based method for searching scientific literature

Eli Marie Grindedal, Kjersti Jørgensen, Pernilla Olsson, Berit Gravdehaug, Hilde Lurås, Ellen Schlichting, Tone Vamre, Teresia Wangensteen, Cecilie Heramb, Lovise Mæhle. Fam Cancer 2020
Times Cited: 5







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
488
40

Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Maira Kentwell, Eryn Dow, Yoland Antill, C David Wrede, Orla McNally, Emily Higgs, Anne Hamilton, Sumitra Ananda, Geoffrey J Lindeman, Clare L Scott. Gynecol Oncol 2017
54
40

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Zoe Kemp, Alice Turnbull, Shawn Yost, Sheila Seal, Shazia Mahamdallie, Emma Poyastro-Pearson, Margaret Warren-Perry, Anthony Eccleston, Min-Min Tan, Soo Hwang Teo,[...]. JAMA Netw Open 2019
23
40

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Angela George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Gore,[...]. Sci Rep 2016
95
40

Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Erin Tutty, Lara Petelin, Joanne McKinley, Mary-Anne Young, Bettina Meiser, Victoria M Rasmussen, Rowan Forbes Shepherd, Paul A James, Laura E Forrest. Eur J Hum Genet 2019
8
40

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
Richard M Brohet, Maria E Velthuizen, Frans B L Hogervorst, Hanne E J Meijers-Heijboer, Caroline Seynaeve, Margriet J Collée, Senno Verhoef, Margreet G E M Ausems, Nicoline Hoogerbrugge, Christi J van Asperen,[...]. J Med Genet 2014
56
20

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Muriel A Adank, Marianne A Jonker, Irma Kluijt, Saskia E van Mil, Rogier A Oldenburg, Wolter J Mooi, Frans B L Hogervorst, Ans M W van den Ouweland, Johan J P Gille, Marjanka K Schmidt,[...]. J Med Genet 2011
41
20

Beyond BRCA: new hereditary breast cancer susceptibility genes.
P Economopoulou, G Dimitriadis, A Psyrri. Cancer Treat Rev 2015
90
20

The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Olivia M Valencia, Selyne E Samuel, Rebecca K Viscusi, Taylor S Riall, Leigh A Neumayer, Hassan Aziz. JAMA Surg 2017
38
20

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
Mark E Robson, Courtney D Storm, Jeffrey Weitzel, Dana S Wollins, Kenneth Offit. J Clin Oncol 2010
295
20

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Marjanka K Schmidt, Frans Hogervorst, Richard van Hien, Sten Cornelissen, Annegien Broeks, Muriel A Adank, Hanne Meijers, Quinten Waisfisz, Antoinette Hollestelle, Mieke Schutte,[...]. J Clin Oncol 2016
74
20

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Hanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, Marijke Wasielewski, Anja de Snoo, Rogier Oldenburg, Antoinette Hollestelle, Mark Houben, Ellen Crepin, Monique van Veghel-Plandsoen,[...]. Nat Genet 2002
767
20

A duty to recontact in genetics: context matters.
Noor A A Giesbertz, Wim H van Harten, Annelien L Bredenoord. Nat Rev Genet 2019
5
20

A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.
Deborah Thompson, Sheila Seal, Mieke Schutte, Lesley McGuffog, Rita Barfoot, Anthony Renwick, Rosalind Eeles, Nayanta Sodha, Richard Houlston, Susan Shanley,[...]. Cancer Epidemiol Biomarkers Prev 2006
38
20


Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature.
Ellen Otten, Mirjam Plantinga, Erwin Birnie, Marian A Verkerk, Anneke M Lucassen, Adelita V Ranchor, Irene M Van Langen. Genet Med 2015
47
20

Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Taru A Muranen, Dario Greco, Carl Blomqvist, Kristiina Aittomäki, Sofia Khan, Frans Hogervorst, Senno Verhoef, Paul D P Pharoah, Alison M Dunning, Mitul Shah,[...]. Genet Med 2017
43
20


[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
Muriel A Adank, Frederik J Hes, Wendy A G van Zelst-Stams, M Petrousjka van den Tol, Caroline Seynaeve, Jan C Oosterwijk. Ned Tijdschr Geneeskd 2015
7
20

CHEK2 mutations and the risk of papillary thyroid cancer.
Monika Siołek, Cezary Cybulski, Danuta Gąsior-Perczak, Artur Kowalik, Beata Kozak-Klonowska, Aldona Kowalska, Małgorzata Chłopek, Wojciech Kluźniak, Dominika Wokołorczyk, Iwona Pałyga,[...]. Int J Cancer 2015
60
20

Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial.
Marijke R Wevers, Margreet G E M Ausems, Senno Verhoef, Eveline M A Bleiker, Daniela E E Hahn, Titia Brouwer, Frans B L Hogervorst, Rob B van der Luijt, Thijs van Dalen, Evert B Theunissen,[...]. Genet Med 2016
16
20

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.
Victoria Hale, Maren Weischer, Jong Y Park. Prostate Cancer 2014
32
20

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Davide Angeli, Samanta Salvi, Gianluca Tedaldi. Int J Mol Sci 2020
13
20

The risk of gastric cancer in carriers of CHEK2 mutations.
Urszula Teodorczyk, Cezary Cybulski, Dominika Wokołorczyk, Anna Jakubowska, Teresa Starzyńska, Małgorzata Lawniczak, Paweł Domagała, Katarzyna Ferenc, Krzysztof Marlicz, Zbigniew Banaszkiewicz,[...]. Fam Cancer 2013
31
20

Recontact in clinical practice: a survey of clinical genetics services in the United Kingdom.
Daniele Carrieri, Anneke M Lucassen, Angus J Clarke, Sandi Dheensa, Shane Doheny, Peter D Turnpenny, Susan E Kelly. Genet Med 2016
25
20

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Maren Weischer, Stig Egil Bojesen, Christina Ellervik, Anne Tybjaerg-Hansen, Børge Grønne Nordestgaard. J Clin Oncol 2008
182
20

A clinical perspective on ethical issues in genetic testing.
R H Sijmons, I M Van Langen, J G Sijmons. Account Res 2011
13
20


Psychological distress and use of psychosocial support in familial adenomatous polyposis.
Kirsten F L Douma, Neil K Aaronson, Hans F A Vasen, Miranda A Gerritsma, Chad M Gundy, Esther P A Janssen, Annette H J T Vriends, Annemieke Cats, Senno Verhoef, Eveline M A Bleiker. Psychooncology 2010
58
20

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
Maren Weischer, Børge G Nordestgaard, Paul Pharoah, Manjeet K Bolla, Heli Nevanlinna, Laura J Van't Veer, Montserrat Garcia-Closas, John L Hopper, Per Hall, Irene L Andrulis,[...]. J Clin Oncol 2012
103
20

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
G H de Bock, M Schutte, E M M Krol-Warmerdam, C Seynaeve, J Blom, C T M Brekelmans, H Meijers-Heijboer, C J van Asperen, C J Cornelisse, P Devilee,[...]. J Med Genet 2004
80
20

Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.
Minerva A Romero Arenas, Thereasa A Rich, Samuel M Hyde, Naifa L Busaidy, Gilbert J Cote, Mimi I Hu, Robert F Gagel, Paul W Gidley, Camilo Jimenez, Michael E Kupferman,[...]. Ann Surg Oncol 2018
8
20


Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
Allison W Kurian, Bronislava M Sigal, Sylvia K Plevritis. J Clin Oncol 2010
150
20


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
20

The Angelina Jolie effect.
Paul A James, Gillian Mitchell, Michael Bogwitz, Geoffrey J Lindeman. Med J Aust 2013
22
20

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
20

Medicare-funded cancer genetic tests: a note of caution.
Judy Kirk, Kristine K Barlow-Stewart, Nicola K Poplawski, Margaret Gleeson, Kathy Tucker, Michael Friedlander. Med J Aust 2018
5
20

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
20

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
295
20

Mastering genomic terminology.
Gail P Jarvik, James P Evans. Genet Med 2017
10
20

The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
M Gleeson, M Kentwell, B Meiser, J Do, S Nevin, N Taylor, K Barlow-Stewart, J Kirk, P James, C L Scott,[...]. Gynecol Oncol 2020
4
25

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
20


Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome.
Steve Heymann, Suzette Delaloge, Arslane Rahal, Olivier Caron, Thierry Frebourg, Lise Barreau, Corinne Pachet, Marie-Christine Mathieu, Hugo Marsiglia, Céline Bourgier. Radiat Oncol 2010
105
20

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
A J Lee, A P Cunningham, K B Kuchenbaecker, N Mavaddat, D F Easton, A C Antoniou. Br J Cancer 2014
132
20

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini. Ann Oncol 2018
103
20

Breast Cancer Genetic Counseling: A Surgeon's Perspective.
Doreen M Agnese, Raphael E Pollock. Front Surg 2016
7
20

Relationships Between Health Literacy and Genomics-Related Knowledge, Self-Efficacy, Perceived Importance, and Communication in a Medically Underserved Population.
Kimberly A Kaphingst, Melvin Blanchard, Laurel Milam, Manusheela Pokharel, Ashley Elrick, Melody S Goodman. J Health Commun 2016
35
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.